PolyPid Ltd. (PYPD) Form 6-K — Oct 1, 2026
PolyPid announced that the EMA validated its Marketing Authorization Application for D-PLEX100, its lead candidate for preventing post-abdominal surgery incisional infections. Validation, submitted September 14, 2026, confirms the application is complete and initiates formal review by the EMA's CHMP. The application is supported by the positive Phase 3 SHIELD II trial, which met its primary endpoint and showed a 60% relative risk reduction in surgical site infections versus standard of care (p=0.0013). If approved, D-PLEX100 would receive marketing authorization across all EU member states.
Key figures
- Pdufa date
- 2026-11-28
- Phase3 p value
- 0.0013
- Maa submission date
- 2026-09-14
- Drug release duration days
- 30
- Ssi relative risk reduction
- 60%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.